Mesoblast
is an Australia-based regenerative medicine company that develops allogeneic cellular medicines for the treatment of inflammatory and cardiovascular diseases... Read moreMesoblast
is an Australia-based regenerative medicine company that develops allogeneic cellular medicines for the treatment of inflammatory and cardiovascular diseases... Read more
News
Apr 17, 2025
GlobeNewswire
Press Release: Mesoblast : Mesoblast Extends Payer Coverage For Ryoncil to Over 100 Million US Lives
Apr 14, 2025
Kalkine Media
Mesoblast: Mesoblast Limited Announces Quotation of New Securities
Apr 04, 2025
Life Care News
Mesoblast: Mesoblast Allogeneic Cell Therapy Products Are Designated U.S. Country of Origin and Not Subject to U.S. Tariffs
Apr 03, 2025
Americanbankingnews
Mesoblast: FY2025 EPS Estimates for Mesoblast Decreased by Analyst
Apr 02, 2025
StreetInsider
Press Release: Mesoblast : Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor in Ischemic Heart Failure
Mar 31, 2025
Finance News Network
Mesoblast: Mesoblast's Ryoncil Receives US Medicaid Coverage
Mar 30, 2025
GlobeNewswire
Press Release: Mesoblast : First Three Children to Commence Treatment With Ryoncil
Mar 27, 2025
GlobeNewswire
Press Release: Mesoblast : Ryoncil is Now Available for Purchase in the United States
Mar 12, 2025
Benzinga
Mesoblast: Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall
Mar 07, 2025
Life Care News
Mesoblast: Mesoblast Added to S&P/ASX 200 INDEX
Mesoblast Competitors
1
2
3
4
5
6
7
8
9
10